Article:Dialysis Procedures Alter Metabolic Conditions. (5490527)

From ScienceSource
Jump to: navigation, search

This page is the ScienceSource HTML version of the scholarly article described at Its title is Dialysis Procedures Alter Metabolic Conditions. and the publication date was 2017-05-27. The initial author is Bernd Stegmayr.

Fuller metadata can be found in the Wikidata link, which lists all authors, and may have detailed items for some or all of them. There is further information on the article in the footer below. This page is a reference version, and is protected against editing.

Converted JATS paper:

Journal Information

Title: Nutrients

Dialysis Procedures Alter Metabolic Conditions

  • Bernd Stegmayr

Department of Public Health and Clinical Medicine, Umea University, 90187 Umea, Sweden;

Publication date (epub): 5/2017

Publication date (collection): 6/2017


A progressive chronic kidney disease results in retention of various substances that more or less contribute to dysfunction of various metabolic systems. The accumulated substances are denominated uremic toxins. Although many toxins remain undetected, numerous newly defined toxins participate in the disturbance of food breakdown. In addition, toxic effects may downregulate other pathways, resulting in a reduced ability of free fatty acid breakdown by lipoprotein lipase (LPL) and hepatic lipase (HL). Dialysis may even worsen metabolic functions. For LPL and HL, the use of heparin and low molecular weight heparin as anticoagulation during hemodialysis (HD) initiate a loss of these enzymes from their binding sites and degradation, causing a temporary dysregulation in triglyceride breakdown. This lack of function will cause retention of the triglyceride containing lipids for at least 8 h. In parallel, the breakdown into free fatty acids is limited, as is the energy supply by them. This is repeated thrice a week for a normal HD patient. In addition, dialysis will cause a loss of amino acids and disturb glucose metabolism depending on the dialysates used. The addition of glucose in the dialysate may support oxidation of carbohydrate and the retention of Amadori products and subsequent tissue alterations. To avoid these effects, it seems necessary to further study the effects of anticoagulation in HD, the extent of use of glucose in the dialysate, and the supplementation of amino acids.


1. Chronic Kidney Disease (CKD)

A progressive CKD results in retention of various substances that end up in uremia [[1],[2],[3]] and a need of dialysis or transplantation for survival. Substances may, more or less, contribute to dysfunction of various metabolic systems [[4]]. Accumulated substances are denominated uremic toxins [[1]]. The number of toxins exceeds 1400, and many of them are still unraveled [[5]].

When the glomerular filtration rate is reduced to less than 15 mL/min, the retention of urea and other toxins may lead to a reduced appetite [[6]]. In this situation, a protein restriction will to some extent reduce the concentration of metabolites as urea and reduce uremic symptoms [[7]]. At this stage of chronic kidney disease (CKD), the intestinal flora is altered. Fermentation of protein and amino acids by gut bacteria generates excess amounts of potentially toxic compounds such as ammonia, amines, thiols, phenols, and indoles. In addition, the generation of short-chain fatty acids is reduced. An impaired intestinal barrier function in patients with CKD permits translocation of gut-derived uremic toxins into the systemic circulation. These uremic toxins contribute to the progression of CKD, cardiovascular disease, insulin resistance, and protein-energy wasting [[8]]. In parallel, the new intestinal flora may result in bowel dysfunction, with altered stools and worsened appetite.

Progressive weight loss is an important sign of severe kidney dysfunction, and it is an important indicator of dialysis treatment onset if this negative trend of malnutrition is to be broken [[6]].

2. Dialysis

The initiation of adequate doses of dialysis are recommended to limit the side effects of uremic toxins. For hemodialysis (HD), at least three sessions per week and a total time of at least 12 h/w should result in a weekly clearance, eKt/V, of more than 1.2 (for women and patients with high comorbidity 1.4) [[9]].

Dialysis will only partly lower increased levels of various uremic toxins. When performing HD, the lowering of uremic toxins is intermittent for a few hours and thereafter followed by a progressive retention until the next HD [[9]]. During continuous ambulatory peritoneal dialysis (CAPD), the removal of toxins proceeds through the peritoneal membrane. The efficacy of the peritoneal membrane (clearance) is much lower than a hemodialysis membrane. Thereby, the clearance of urea is approximately 4 mL/min [[10],[11]], whereas during intermittent HD the removal rate is 50 times higher (more than 200 mL/min) [[12]]. Continuous, everyday treatment, usually for 24 h/day, compensates for limitations in peritoneal transfer.

Malnutrition, appetite loss, and protein wasting is common despite dialysis treatment and is reported to be present in up to 47% of patients [[13],[14]]. Moreover, besides variables that indicate the presence of inflammation, as increased IL-6 and CRP levels, the dialysis is by itself associated with protein-energy wasting [[15]]. Protein-energy wasting (PEW) refers to the loss or reduced amounts of body protein mass and fuel reserves [[16]]. Too extensive fluid intake and thus inter dialytic weight gain (IDWG) [[17]] and inflammatory processes are variables that interfere with appetite and thus with food intake [[6]]. In addition, the taste acuity is impaired in uremic and dialysis patients [[18]]. The appetite and taste acuity is similarly reduced in HD and peritoneal dialysis (PD) patients [[15],[18]]. However, when inflammation is added, it gets worse. Inflammatory episodes are more frequent with HD than they are with PD [[15]].

3. Triglycerides and Hemodialysis

When malnutrition appears, an increase in protein and calories is often recommended to adjust for the lack of energy [[6]]. Fat contributes to 40% of calories, which derive mainly from triglycerides (TrG) [[19]]. Triglycerides are transported in blood in the core of lipoproteins (chylomicrons and VLDL). Fatty acids (5% by glycerol) contribute to 95% of that energy content. Lipoprotein lipase (LPL) and hepatic lipase (HL) are key enzymes in the breakdown of triglycerides [[20],[21],[22]].

Hyperlipidemia, especially the increase of TrG in all density classes, is present in patients with severe CKD and those on dialysis [[6],[23],[24]]. A limitation in lipid breakdown is present due to the reduced amount and partly inhibited function of lipases [[20],[22],[25],[26],[27]]. The lack of functioning lipase will result in an increased concentration of TrG in the blood. The function of lipases is reduced by increased levels of the enzyme inhibitors angiopoietin-like protein 3, 4, and 8 (ANGPTL) [[22],[28],[29],[30]]. These hepatically derived factors inhibit LPL activity differently. Zhang suggested an ANGPTL3-4-8 model where the ANGPTL8 activates ANGPTL3, in an endocrine manner, to inhibit the activity of LPL activity in the heart and skeletal muscle. On the contrary, ANGPTL4 inhibits LPL activity in white adipose tissue [[30]]. Fasting upregulates ANGPTL4 (inhibiting LPL in fat tissue) and downregulates ANGPTL8, thereby stimulating LPL in heart and sceletal muscle. While ANGPTL8 is not elevated in HD patients [[31]], ANGPTL3 and ANGPTL4 are significantly increased [[29],[32]]. Hemodialysis did not eliminate ANGPTL3, while a high flux dialysis filter is necessary to cause a reduction in ANGPTL4 levels [[29]]. Besides inhibiting factors to LPL, HD patients have only approximately half of the body store of lipases compared with healthy age-matched persons [[33]]. The body store can be estimated by an intravenous bolus dose of heparin that releases most of the LPL and hepatic lipases from their binding sites [[34]]. A peak value of the lipase or area under the curve (AUC) can be used for a comparison between groups [[33]]. The reduction of LPL, upon heparin injection, results in a limitation of breakdown capacity of TrG into FFA and energy. In addition, during HD, in most centers, unfractionated heparin (UFH) and low molecular weight heparin (LMWH) is used in anticoagulation of the extra corporeal circuit to avoid clotting and to maintain an open dialysis circuit [[35]]. The UFH and LMWH will enter the blood of the patient. Here, UFH and LMWH will immediately induce the HL and LPL to lose their binding from the sites at the endothelia, where they are normally attached, and get distributed throughout the blood [[20],[34],[36]]. The release from the binding sites, within minutes, will cause an increase in LPL and HL in the circulation, as well as a subsequent temporary breakdown and reduction of triglycerides [[37]]. The increased lipase activity due to the enzyme now becomes fully exposed to triglycerides in the circulation. In parallel, the liver will rapidly degrade the released LPL and HL, this degradation is differing between unfractionate heparin and low molecular weight heparins [[36],[37]]. This increased degradation will only slowly be compensated for by new enzyme production. It will take at least 8 h to achieve a recovery to baseline capacity [[38],[39]]. The effect will be that the triglycerides will rise significantly during the end of HD. At that stage TrG will not be degraded into FFA and energy in the extent that the body may find necessary for optimal energy supply, especially if the patient intends to be physically active. A metabolic starvation based on lowered capacity of lipid breakdown will be present. In parallel, enzyme inhibitors angiopoietin-like proteins 3 and 4 are at high levels in the blood [[29]]. Since HD is usually repeated at least thrice a week for a normal HD patient, an intermittent disturbance of the lipase system will occur. To avoid the disturbances of the lipases (caused by heparin), it seems necessary to clarify other options of anticoagulation such as regional citrate anticoagulation. By using solely citrate (and not UFH), there is no release of lipase from its endothelial bindings sites [[29]]. If heparin is added, an instant release of the lipases occurs. However, the citrate anticoagulation technique has still not been fully developed for chronic dialysis, using it neither as dialysate [[40]] nor as regional administration [[35]]. At present, the regional citrate dialysis requires more surveillance during HD, especially to secure from deviance from normal values of ionized calcium and magnesium [[41],[42]].

During CAPD, the decreased levels of lipase will partly impair the ability to degrade lipids. However, these patients do not get UFH or LMWH intravenously thrice a week; thereby, the periods of extensive dysfunction of the lipid breakdown system will not appear.

To further clarify these changes, it is important to perform long-term controlled studies with or without reduced doses of intravenous UFH or various types of LMWH as anticoagulation to investigate the possibility of preserving the LPL function at its binding sites.

4. Protein and Dialysis

The protein breakdown into energy is especially disturbed during inflammation. Thereby, protein-energy wasting (PEW) has numerous causes such as anorexia and decreased food intake caused by uremic toxins, inflammation, and superimposed illnesses. In addition, resistance to anabolic hormones, increased oxidant levels, decreased antioxidants, acidemia, and physical deconditioning are important factors to consider [[6]]. Further low-flux HD causes a loss of 1–2 g of protein through the dialyzer, whereas, when high flux membranes are used, the loss of 10 g of amino acids in postprandial patients has been reported [[43],[44],[45]]. Approximately, 3 g/day of free amino acids are removed during CAPD, and 9 g/day of protein and approximately 5.7 g/day of albumin is lost into the dialysate [[46]], which can rise up to more than 15 g/day when peritonitis is present [[46]]. Acidemia can promote protein degradation and aggravate the metabolic disorder [[6]].

5. Carbohydrates and Hemodialysis

Another important energy supply in the dialysis patients is the carbohydrate intake. When the lipase function is impaired, the patients have to rely on glucose metabolism. Therefore, the dietary preference might be of the patient to nourish themselves so as to ingest more carbohydrates. An increased intake of carbohydrates and fat is recommended by dieticians when kidney function is severely impaired (clearance <15 mL/min) and when a protein-restricted diet is prescribed. However, at this stage the body is limited in its carbohydrate metabolism and in addition insulin resistance is usually present [[8],[47],[48],[49],[50]].

When performing CAPD, the patients will be loaded with glucose, due to the transfer of glucose from the PD fluid into the vessels of the abdominal cavity. From there, it diffuses into the body. In normoglycemic individuals, approximately 15–25 g of glucose (200–480 kcal of energy) may be removed during HD when glucose free dialysate is used [[45],[51]]. With glucose containing hemodialysate of 200 mg/dL (10 mmol/L), there is, on the contrary, a net absorption of 10–12 g of glucose/HD [[6]].

During HD, in most European centers, the dialysis fluid will contain glucose at a final concentration of approximately 5 mmol/L. The initial reason for using the glucose within the dialysate is partly to avoid hypoglycemia in patients suffering from diabetes mellitus. However, nowadays, glucose in the dialysate is considered a beneficial supply of energy to the patients.

However, the glucose load from dialysate during HD, especially when using 200 mg/dL [[49]], will disturb metabolism and contribute to oxidative stress and increased blood glucose and serum insulin [[49],[52]]. The increased levels of oxidative radicals induce oxidation of carbohydrates. The oxidation induces glycation, then the retention of Amadori products, and subsequently tissue damage. In short, reactive derivatives from non-enzymatic glucose–protein condensation reactions, as well as lipids and nucleic acids exposed to reducing sugars, form a heterogeneous group of irreversible adducts called AGEs (advanced glycation end products). The glycation process begins with the conversion of reversible Schiff base adducts to more stable, covalently bound Amadori rearrangement products. Over the course of days to weeks, these Amadori products undergo further rearrangement and condensation reactions to form irreversibly cross-linked macroprotein derivatives known as AGEs [[50]]. A method of estimating retained glucose degradation products within the body is the skin-autofluorescence device (SAF) [[53]]. There is a strong correlation between the finding of high values of SAF and the risk for premature death and especially due to cardiovascular causes [[54]]. The impaired kidney function per se will cause retention of Amadori products and rearrangements of tissue, causing more or less cardiovascular alterations [[53]]. HD can be performed using a dialysis membranes with either smaller or larger pores. With a dialysate containing glucose (5 mmol/L), and HD with either low flux or high flux (larger pores) dialyzers, there was no change measured by SAF [[55],[56]]. In contrast, a significant reduction of SAF was measured when performing HD without dialysate glucose [[57]]. Data from high flux HD even indicated the presence of a more extensive backfiltration of glucose through the dialyzer membrane into the blood. This induces subsequent oxidative stress and the presence of higher concentrations of protein-bound glucose degradation products in plasma compared to when HD was performed using low-flux membranes [[56]]. Therefore, these data question a benefit of glucose containing dialysates to compensate for the dysfunction of lipases for energy supply by TrG breakdown during standard HD. However, glucose containing dialysates may prevent severe hypoglycemia in patients with labile insulin-dependent diabetes mellitus [[58]]. To investigate if an improved net balance of glycation degradation products can be achieved over the long term, further studies with low glucose or glucose-free dialysate are recommended.

For CAPD patients, the disadvantage is the extensive glucose load in the dialysis bags, which is continuous throughout the day, unless automated cyclic peritoneal dialysis is used for only part of the day. This may be reflected by the worse skin autofluorescence (SAF) findings in PD versus HD patients, when adjusted for age and dialysis vintage in adults [[59]], but not different in children [[60]]. Besides cardiovascular morbidity and increased mortality, high SAF was related to a greater risk for sepsis-related mortality in PD patients [[61]]. Negative factors for a high SAF were long dialysis vintage and cumulative glucose exposure [[59],[62]]. Patients using icodextrin (Baxter Inc., Deerfield, IL, USA), instead of glucose, as a dialysate had worse SAF than those using glucose only [[63]]. An indication for the possible reversibility is the finding that patients transplanted had SAF similar to patients with chronic kidney disease stage 3 and less than those on HD and PD [[64]].

6. Consideration of Diet for Dialysis Patients

When confronted with the patient therapeutic strategies to prevent and treat protein-energy wasting in maintenance dialysis, patients are to optimize the dialysis and limit the inflammatory processes. A general investigation should include the evaluation of body size, nutrient intake, and protein-energy wasting with the periodic help of dietary counseling and monitoring of nutrient intake and protein-energy status. The use of inter dialytic weight gain can help to guide patient nutrition and compliance [[6],[17]]. Patients on HD, with heparin as anticoagulation, may benefit from limitation in intake of larger amounts of fat during the HD procedure per se and a few hours thereafter, especially if they suffer from increased blood levels of TrG. Risk of hypoglycemia or presence of severe malnutrition has to be taken into account when removal of glucose in the dialysate is considered. When glucose is used, a concentration of 5 mmol/L seems preferable to 10 mmol/L. Further studies have to clarify whether a lower dialysate glucose concentration or total withdrawal should be compensated for by a protein- and glucose-enriched diet. Patients randomized to receive inter dialytic parenteral nutrition (IDPN), in comparison to those not receiving IDPN, did not show, over two years, improved mortality or hospitalization rates, nor reduced evidence for PEW [[65]]. Lack of difference may be due to the fact that almost all of the patients received an oral nutritional supplement as well. The use of oral supplement may alone improve whole-body and skeletal muscle protein anabolism in a dose-dependent manner in chronic HD patients [[65],[66]].

The periods between HD seem metabolically optimal for food intake and exercise, since the lipase restores within approximately 4 h after HD. Guidelines recommend intake of approximately 1.2 g/kg/day 50% high biologic value protein and 35 kcal/kg/day (fat 25–35% of total energy intake, <7% saturated fat), unless older than 60 years and/or those with limited exercise or obese [[6]].

Since the HD per se will induce protein catabolism [[67]], the use of low and high flux dialyzers may further contribute to the loss of amino acids [[68],[69],[70],[71],[72]]. The HD procedure, metabolic disturbance, and reduced extent of exercise can well explain that the working capacity of HD patients is extensively reduced compared to age-matched persons without chronic kidney disease [[73]].

For CAPD patients, there might be a benefit calculating the PD-glucose adsorbed/day by peritoneal transfer through the membrane. This glucose load can help to adjust the content of various nutrients for the daily intake. Adding one amino acid bag instead of glucose reduces the glucose load [[6]]. This change into an amino acid bag may help to limit protein losses by dialysis [[74],[75]].

For patients with diabetes mellitus the risk for hypo- and hyperglycemia needs to be considered [[76]], and it can well motivate to maintain a glucose containing dialysate in these patients.


  1. R. VanholderA. ArgilesU. BaurmeisterP. BrunetW. ClarkG. CohenP.P. De DeynR. DeppischB. Descamps-LatschaT. HenleUremic toxicity: Present state of the artInt. J. Artif. Organs20012469572511817319
  2. R. VanholderR. De SmetG. GlorieuxA. ArgilesU. BaurmeisterP. BrunetW. ClarkG. CohenP.P. De DeynR. DeppischReview on uremic toxins: Classification, concentration, and interindividual variabilityKidney Int.2003631934194310.1046/j.1523-1755.2003.00924.x12675874
  3. F. DurantonG. CohenR. De SmetM. RodriguezJ. JankowskiR. VanholderA. ArgilesEuropean Uremic Toxin Work GroupNormal and pathologic concentrations of uremic toxinsJ. Am. Soc. Nephrol.2012231258127010.1681/ASN.201112117522626821
  4. R. VanholderE. SchepersA. PletinckE.V. NaglerG. GlorieuxThe uremic toxicity of indoxyl sulfate and p-cresyl sulfate: A systematic reviewJ. Am. Soc. Nephrol.2014251897190710.1681/ASN.201310106224812165
  5. E.M. WeissingerT. KaiserN. MeertR. De SmetM. WaldenH. MischakR.C. VanholderProteomics: A novel tool to unravel the patho-physiology of uraemiaNephrol. Dial. Transplant.2004193068307710.1093/ndt/gfh50915494356
  6. J.D. KoppleA. ShahK. Kalantar-ZadehMalnutrition and Intradialytic Parenteral Nutrition in End-Stage Kidney Disease PatientsPrinciples and Practice of Dialysis5th ed.E.V. LermaM.R. WeirWolters KluwerPhiladelphia, PA, USA2017445464
  7. A. AlvestrandM. AhlbergP. FurstJ. BergstromClinical results of long-term treatment with a low protein diet and a new amino acid preparation in patients with chronic uremiaClin. Nephrol.19831967736839554
  8. A. RamezaniZ.A. MassyB. MeijersP. EvenepoelR. VanholderD.S. RajRole of the Gut Microbiome in Uremia: A Potential Therapeutic TargetAm. J. Kidney Dis.20166748349810.1053/j.ajkd.2015.09.02726590448
  9. M.K. KuhlmannP. KotankoN.W. LevinHemodialysis: Outcome and AdequacyComprehensive Clinical NephrologyR.J. JohnsonJ. FeehallyJ. FloegeElsevierPhiladelphia, PA, USA201510751083
  10. M. WolfsonB. PirainoR.J. HamburgerA.R. MortonIcodextrin Study GroupA randomized controlled trial to evaluate the efficacy and safety of icodextrin in peritoneal dialysisAm. J. Kidney Dis.2002401055106510.1053/ajkd.2002.3634412407652
  11. J. PlumS. GentileC. VergerR. BrunkhorstU. BahnerB. FallerJ. PeetersP. FreidaD.G. StruijkR.T. KredietEfficacy and safety of a 7.5% icodextrin peritoneal dialysis solution in patients treated with automated peritoneal dialysisAm. J. Kidney Dis.20023986287110.1053/ajkd.2002.3200911920355
  12. Revaclear Dialyzer TechnologyBaxter Inc.Deerfield, IL, USAAvailable online: on 27 April 2017)
  13. J.J. CarreroA.R. QureshiJ. AxelssonC.M. AvesaniM.E. SulimanS. KatoP. BaranyS. Snaedal-JonsdottirA. AlvestrandO. HeimburgerComparison of nutritional and inflammatory markers in dialysis patients with reduced appetiteAm. J. Clin. Nutr.20078569570117344489
  14. J.J. CarreroA. NakashimaA.R. QureshiB. LindholmO. HeimburgerP. BaranyP. StenvinkelProtein-energy wasting modifies the association of ghrelin with inflammation, leptin, and mortality in hemodialysis patientsKidney Int.20117974975610.1038/ki.2010.48721178976
  15. S. SnaedalA.R. QureshiS.H. LundG. GermanisB. HylanderO. HeimburgerJ.J. CarreroP. StenvinkelP. BaranyDialysis modality and nutritional status are associated with variability of inflammatory markersNephrol. Dial. Transplant.2016311320132710.1093/ndt/gfw10427220753
  16. D. FouqueK. Kalantar-ZadehJ. KoppleN. CanoP. ChauveauL. CuppariH. FranchG. GuarnieriT.A. IkizlerG. KaysenA proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney diseaseKidney Int.20087339139810.1038/
  17. B. HolmbergB.G. StegmayrCardiovascular conditions in hemodialysis patients may be worsened by extensive interdialytic weight gainHemodial. Int.200913273110.1111/j.1542-4758.2009.00335.x19210274
  18. A. FernstromB. HylanderS. RossnerTaste acuity in patients with chronic renal failureClin. Nephrol.1996451691748706357
  19. M. Van der GietM. TolleD. PraticoV. LufftM. SchuchardtM.P. HorlW. ZidekU.J. TietgeIncreased type IIA secretory phospholipase A(2) expression contributes to oxidative stress in end-stage renal diseaseJ. Mol. Med.201088758310.1007/s00109-009-0543-319798476
  20. B. StegmayrUremic toxins and lipases in haemodialysis: A process of repeated metabolic starvationToxins201461505151110.3390/toxins605150524784324
  21. G. Van HallThe Physiological Regulation of Skeletal Muscle Fatty Acid Supply and Oxidation During Moderate-Intensity ExerciseSports Med.201545S23S3210.1007/s40279-015-0394-826553490
  22. N. FlorensC. CalzadaE. LyaskoL. JuillardC.O. SoulageModified Lipids and Lipoproteins in Chronic Kidney Disease: A New Class of Uremic ToxinsToxins2016837610.3390/toxins812037627999257
  23. J.D. BagdadeUremic lipemia. An unrecognized abnormality in triglyceride production and removalArch. Intern. Med.197012687588110.1001/archinte.1970.003101101450265475714
  24. P.O. AttmanP. AlaupovicM. TavellaC. Knight-GibsonAbnormal lipid and apolipoprotein composition of major lipoprotein density classes in patients with chronic renal failureNephrol. Dial. Transplant.199611636910.1093/ndt/11.1.638649654
  25. J.D. BagdadeE. YeeD.E. WilsonShafrirHyperlipidemia in renal failure: Studies of plasma lipoproteins, hepatic triglyceride production, and tissue lipoprotein lipase in a chronically uremic rat moedlJ. Lab. Clin. Med.19789117618622574
  26. N.D. VaziriCauses of dysregulation of lipid metabolism in chronic renal failureSemin. Dial.20092264465110.1111/j.1525-139X.2009.00661.x20017835
  27. N.D. VaziriJ. YuanZ. NiS.B. NicholasK.C. NorrisLipoprotein lipase deficiency in chronic kidney disease is accompanied by down-regulation of endothelial GPIHBP1 expressionClin. Exp. Nephrol.20121623824310.1007/s10157-011-0549-322009636
  28. A.K. CheungC.J. ParkerK. RenP.H. IveriusIncreased lipase inhibition in uremia: Identification of pre-beta-HDL as a major inhibitor in normal and uremic plasmaKidney Int.1996491360137110.1038/ki.1996.1928731101
  29. D. MahmoodE. MakoveichukS. NilssonG. OlivecronaB. StegmayrResponse of angiopoietin-like proteins 3 and 4 to hemodialysisInt. J. Artif. Organs201437132010.5301/ijao.500025224634330
  30. R. ZhangThe ANGPTL3–4-8 model, a molecular mechanism for triglyceride traffickingOpen Biol.2016615027210.1098/rsob.15027227053679
  31. T. EbertS. KralischA. HoffmannA. BachmannU. LossnerJ. KratzschM. BluherM. StumvollA. TonjesM. FasshauerCirculating angiopoietin-like protein 8 is independently associated with fasting plasma glucose and type 2 diabetes mellitusJ. Clin. Endocrinol. Metab.201499E2510E251710.1210/jc.2013-434925325797
  32. T. BaranowskiS. KralischA. BachmannU. LossnerJ. KratzschM. BluherM. StumvollM. FasshauerSerum levels of the adipokine fasting-induced adipose factor/angiopoietin-like protein 4 depend on renal functionHorm. Metab. Res.20114311712010.1055/s-0030-126791720972945
  33. B. NasstromG. OlivecronaT. OlivecronaB.G. StegmayrLipoprotein lipase during heparin infusion: Lower activity in hemodialysis patientsScand. J. Clin. Lab. Investig.200363455310.1080/0036551031000048412729069
  34. B. NasstromG. OlivecronaT. OlivecronaB.G. StegmayrLipoprotein lipase during continuous heparin infusion: Tissue stores become partially depletedJ. Lab. Clin. Med.200113820621310.1067/mlc.2001.11766611528374
  35. M. KesslerF. MoureauP. NguyenAnticoagulation in Chronic Hemodialysis: Progress Toward an Optimal ApproachSemin. Dial.20152847448910.1111/sdi.1238025913603
  36. D. MahmoodM. GrubbstromL.D. LundbergG. OlivecronaT. OlivecronaB.G. StegmayrLipoprotein lipase responds similarly to tinzaparin as to conventional heparin during hemodialysisBMC Nephrol.2010113310.1186/1471-2369-11-3321129229
  37. B. NasstromB.G. StegmayrG. OlivecronaT. OlivecronaLower plasma levels of lipoprotein lipase after infusion of low molecular weight heparin than after administration of conventional heparin indicate more rapid catabolism of the enzymeJ. Lab. Clin. Med.2003142909910.1016/S0022-2143(03)00059-312960955
  38. B. StegmayrT. OlivecronaG. OlivecronaLipoprotein lipase disturbances induced by uremia and hemodialysisSemin. Dial.20092244244410.1111/j.1525-139X.2009.00597.x19708998
  39. B. NasstromB. StegmayrJ. GuptaG. OlivecronaT. OlivecronaA single bolus of a low molecular weight heparin to patients on haemodialysis depletes lipoprotein lipase stores and retards triglyceride clearingNephrol. Dial. Transplant.2005201172117910.1093/ndt/gfh77415797889
  40. B.G. StegmayrP. JonssonD. MahmoodA significant proportion of patients treated with citrate containing dialysate need additional anticoagulationInt. J. Artif. Organs2013361610.5301/ijao.500017223280073
  41. J. Kozik-JarominV. NierU. HeemannB. KreymannJ. BohlerCitrate pharmacokinetics and calcium levels during high-flux dialysis with regional citrate anticoagulationNephrol. Dial. Transplant.2009242244225110.1093/ndt/gfp01719196824
  42. M. BrandlK. StroblJ. HartmannK. KellnerT. PosnicekD. FalkenhagenA target-orientated algorithm for regional citrate-calcium anticoagulation in extracorporeal therapiesBlood Purif.20123372010.1159/00033239422085810
  43. C. ChazotE. ShahmirB. MatiasS. LaidlawJ.D. KoppleDialytic nutrition: Provision of amino acids in dialysate during hemodialysisKidney Int.1997521663167010.1038/ki.1997.5009407515
  44. T.A. IkizlerP.J. FlakollR.A. ParkerR.M. HakimAmino acid and albumin losses during hemodialysisKidney Int.19944683083710.1038/ki.1994.3397996804
  45. Y. LiuX. XiaoD.P. QinR.S. TanX.S. ZhongD.Y. ZhouY. LiuX. XiongY.Y. ZhengComparison of Intradialytic Parenteral Nutrition with Glucose or Amino Acid Mixtures in Maintenance Hemodialysis PatientsNutrients2016822010.3390/nu806022027271658
  46. M.J. BlumenkrantzG.M. GahlJ.D. KoppleA.V. KamdarM.R. JonesM. KesselJ.W. CoburnProtein losses during peritoneal dialysisKidney Int.19811959360210.1038/ki.1981.577241892
  47. V. RigalleauH. GinCarbohydrate metabolism in uraemiaCurr. Opin. Clin. Nutr. Metab. Care2005846346910.1097/01.mco.0000172590.32564.b915930975
  48. R. Czabak-GarbaczD. SchneditzE. ZierlerE. EichmannG. HarterH. Hafner-GiessaufB. Obermayer-PietschBlunted insulinemia using high dialysate glucose concentration during hemodialysisASAIO J.20115744445010.1097/MAT.0b013e318229aaa421869620
  49. J.G. RaimannA. KruseS. ThijssenV. KuntsevichP. DabelM. BacharJ.A. Diaz-BuxoN.W. LevinP. KotankoMetabolic effects of dialyzate glucose in chronic hemodialysis: Results from a prospective, randomized crossover trialNephrol. Dial. Transplant.2012271559156810.1093/ndt/gfr52021940484
  50. S. YamagishiT. MatsuiPathologic role of dietary advanced glycation end products in cardiometabolic disorders, and therapeutic interventionNutrition20163215716510.1016/j.nut.2015.08.00126602289
  51. R.L. WathenP. KeshaviahP. HommeyerK. CadwellC.M. ComtyThe metabolic effects of hemodialysis with and without glucose in the dialysateAm. J. Clin. Nutr.19783118701875707341
  52. C. LimkunakulM.B. SundellB. PouliotA.J. GravesA. ShintaniT.A. IkizlerGlycemic load is associated with oxidative stress among prevalent maintenance hemodialysis patientsNephrol. Dial. Transplant.2014291047105310.1093/ndt/gft48924353320
  53. S. ArsovR. GraaffW. van OeverenB. StegmayrA. SikoleG. RakhorstA.J. SmitAdvanced glycation end-products and skin autofluorescence in end-stage renal disease: A reviewClin. Chem. Lab. Med.201452112010.1515/cclm-2012-083223612551
  54. R. MeerwaldtJ.W. HartogR. GraaffR.J. HuismanT.P. LinksN.C. den HollanderS.R. ThorpeJ.W. BaynesG. NavisR.O. GansSkin autofluorescence, a measure of cumulative metabolic stress and advanced glycation end products, predicts mortality in hemodialysis patientsJ. Am. Soc. Nephrol.2005163687369310.1681/ASN.200502014416280473
  55. R. GraaffS. ArsovB. RamsauerM. KoetsierN. SundvallG.E. EngelsA. SikoleL. LundbergG. RakhorstB. StegmayrSkin and plasma autofluorescence during hemodialysis: A pilot studyArtif. Organs20143851551810.1111/aor.1220524164288
  56. B. RamsauerG. EngelsS. ArsovH. HadimeriA. SikoleR. GraaffB. StegmayrComparing changes in plasma and skin autofluorescence in low-flux versus high-flux hemodialysisInt. J. Artif. Organs20153848849310.5301/ijao.500043426481293
  57. B. RamsauerG.E. EngelsR. GraaffA. SikoleS. ArsovB. StegmayrSkin- and Plasmaautofluorescence in hemodialysis with glucose-free or glucose-containing dialysateBMC Nephrol.201718510.1186/s12882-016-0418-028056864
  58. M. AbeK. Kalantar-ZadehHaemodialysis-induced hypoglycaemia and glycaemic disarraysNat. Rev. Nephrol.20151130231310.1038/nrneph.2015.3825848881
  59. J. JiangP. ChenJ. ChenX. YuD. XieC. MeiF. XiongW. ShiW. ZhouX. LiuAccumulation of tissue advanced glycation end products correlated with glucose exposure dose and associated with cardiovascular morbidity in patients on peritoneal dialysisAtherosclerosis201222418719410.1016/j.atherosclerosis.2012.06.02222857897
  60. I. MakulskaM. SzczepanskaD. DrozdzD. Polak-JonkiszD. ZwolinskaSkin autofluorescence as a marker of cardiovascular risk in children with chronic kidney diseasePediatr. Nephrol.20132812112810.1007/s00467-012-2280-z22976887
  61. D. SiriopolS. HogasG. VeisaI. MititiucC. VolovatM. ApetriiM. OnofriescuI. BusilaM. OleniucA. CovicTissue advanced glycation end products (AGEs), measured by skin autofluorescence, predict mortality in peritoneal dialysisInt. Urol. Nephrol.20154756356910.1007/s11255-014-0870-325425437
  62. E. MacsaiA. BenkeI. KissSkin Autofluorescence and Mortality in Patients on Peritoneal DialysisMedicine201594e193310.1097/MD.000000000000193326559261
  63. E. MacsaiA. BenkeA. CsehB. VasarhelyiFactors influencing skin autofluorescence of patients with peritoneal dialysisActa Physiol. Hung.20129921622210.1556/APhysiol.99.2012.2.1522849846
  64. L.E. CrowleyC.P. JohnsonN. McIntyreR.J. FluckC.W. McIntyreM.W. TaalJ.C. LeungTissue advanced glycation end product deposition after kidney transplantationNephron Clin. Pract.2013124545910.1159/00035569224135496
  65. N.J. CanoD. FouqueH. RothM. AparicioR. AzarB. CanaudP. ChauveauC. CombeM. LavilleX.M. LeverveIntradialytic parenteral nutrition does not improve survival in malnourished hemodialysis patients: A 2-year multicenter, prospective, randomized studyJ. Am. Soc. Nephrol.2007182583259110.1681/ASN.200702018417656473
  66. M.B. SundellK.L. CavanaughP. WuA. ShintaniR.M. HakimT.A. IkizlerOral protein supplementation alone improves anabolism in a dose-dependent manner in chronic hemodialysis patientsJ. Ren. Nutr.20091941242110.1053/j.jrn.2009.01.01919500999
  67. A. GutierrezJ. BergstromA. AlvestrandHemodialysis-associated protein catabolism with and without glucose in the dialysis fluidKidney Int.19944681482210.1038/ki.1994.3377996803
  68. E.D. HynoteM.A. McCamishT.A. DepnerP.A. DavisAmino acid losses during hemodialysis: Effects of high-solute flux and parenteral nutrition in acute renal failureJ. Parenter. Enteral Nutr.199519152110.1177/0148607195019001157658594
  69. A. GutierrezProtein catabolism in maintenance haemodialysis: The influence of the dialysis membraneNephrol. Dial. Transplant.19961110811110.1093/ndt/11.supp2.1088804008
  70. H.W. GilJ.O. YangE.Y. LeeE.M. LeeJ.S. ChoiS.Y. HongThe effect of dialysis membrane flux on amino acid loss in hemodialysis patientsJ. Korean Med. Sci.20072259860310.3346/jkms.2007.22.4.59817728495
  71. A. UmberM.J. WolleyT.A. GolperM.J. ShaverM.R. MarshallAmino acid losses during sustained low efficiency dialysis in critically ill patients with acute kidney injuryClin. Nephrol.201481939910.5414/CN10798224290407
  72. M. MineshimaThe past, present and future of the dialyzerContrib. Nephrol.201518581426023010
  73. E. SterkyB.G. StegmayrElderly patients on haemodialysis have 50% less functional capacity than gender- and age-matched healthy subjectsScand. J. Urol. Nephrol.20053942343010.1080/0036559050019931916257846
  74. M. JonesT. HagenC.A. BoyleE. VoneshR. HamburgerC. CharytanS. SandroniD. BernardB. PirainoM. SchreiberTreatment of malnutrition with 1.1% amino acid peritoneal dialysis solution: results of a multicenter outpatient studyAm. J. Kidney Dis.19983276176910.1016/S0272-6386(98)70131-39820445
  75. M.R. JonesT.W. GehrJ.M. BurkartR.J. HamburgerA.P. Kraus Jr.B.M. PirainoT. HagenF.G. OgrincM. WolfsonReplacement of amino acid and protein losses with 1.1% amino acid peritoneal dialysis solutionPerit. Dial. Int.1998182102169576371
  76. J.E. BurmeisterR. Miltersteiner DdaB.O. BurmeisterJ.F. CamposRisk of hypoglycemia during hemodialysis in diabetic patients is related to lower pre-dialysis glycemiaArch. Endocrinol. Metab.20155913714010.1590/2359-399700000002625993676
The underlying source XML for this text is taken from The license for the article is Creative Commons Attribution. The main subject has been identified as Dialysis.